Five years after MRTA, New York's adult-use market still looks like a slow-motion rollout

On March 31, 2021, Governor Andrew Cuomo signed the Marijuana Regulation and Taxation Act (MRTA) (Chapter 92 of 2021) and New York became the 16th US state to legalize adult-use cannabis. The framework was ambitious: a Cannabis Control Board, a brand-new Office of Cannabis Management, a social-equity-first licensing strategy that prioritized applicants with prior cannabis convictions or impacted communities, and a tax structure that funneled significant revenue back to municipalities.

Five years on, the verdict is mixed. New York has a functioning adult-use market (by 2026 standards, a meaningful one) but the rollout has been one of the slowest among legalized states, and a parallel underground market continues to operate at scale across New York City, Long Island, and the Hudson Valley.

What MRTA did, and what took five years to actually do

The statute's headline provisions took effect immediately: adult possession of 3 ounces of flower and 24 grams of concentrate became legal on the day Cuomo signed. So did the 5-pound in-residence limit. So did the elimination of cannabis-possession arrests for any quantity within the legal cap. So did the expungement of past low-level possession convictions.

The infrastructure took longer. The Cannabis Control Board did not approve its first Conditional Adult-Use Retail Dispensary (CAURD) licenses until late 2022. The first legal recreational dispensary opened in Manhattan in December 2022. Twenty-one months after MRTA's signing. The home-cultivation rights for adult-use users were statutorily delayed to 18 months after retail sales began, which translated to approximately June 2024. Three years post-MRTA.

By comparison, neighboring Massachusetts opened its first adult-use store two years after statutory legalization, and Illinois opened its first store on day one of its January 2020 legalization. New York's pace is slower than both, and most slower-rollout factors trace to the social-equity licensing structure rather than to any single bottleneck.

The social-equity-first design

MRTA explicitly prioritized justice-impacted applicants (individuals previously convicted of cannabis-related offenses, or their immediate family members) for early retail licenses. The CAURD program required applicants to demonstrate prior conviction history plus business-management experience and operating capital.

This was a policy choice with genuine moral logic and significant operational cost. The CAURD application process produced extended litigation in 2023 and 2024 (the Variscite NY One federal court challenge being the most consequential), which froze license issuance for months at a time. Court rulings forced OCM to revisit its application scoring methodology, slow license approvals, and ultimately accept a broader applicant pool than the initial CAURD framework contemplated.

Whether the social-equity prioritization can be judged a success depends on what is being measured. The framework has produced a more demographically diverse retail-license base than any other US state. It has also produced fewer total licensed retailers per capita than any other major legalized state: a structural gap that an underground market (estimated at thousands of unlicensed New York City "smoke shops" and delivery services) was eager to fill.

The medical program's quieter expansion

If the adult-use rollout has been MRTA's headline story, the medical program's evolution has been the quieter one; and arguably more consequential for patient access.

The 2014 Compassionate Care Act originally established New York's medical program with a narrowly enumerated list of qualifying conditions and a non-smokable-product restriction. The 2022 OCM expansion eliminated both constraints: practitioners now certify patients based on clinical judgment rather than a gating list, and the full product spectrum (flower, edibles, vapes, topicals) is available to certified patients.

The practitioner-discretion standard is the most permissive in the United States. Any registered physician, nurse practitioner, or physician assistant may certify a patient for a condition they reasonably believe medical cannabis will improve. The pre-2022 enumerated list (cancer, HIV/AIDS, ALS, Parkinson's, MS, neuropathies, IBD, epilepsy, chronic pain, PTSD, others) functions now as a reference rather than a gate.

What MRTA didn't do

The statute did not formally end the unlicensed cannabis market (it could not, given federal scheduling) but the slow pace of licensed retail rollout left a large enforcement vacuum that the unlicensed market filled. New York City's "smoke shop" proliferation (estimated at 1,400+ stores at peak in 2024) led to a 2024–2025 enforcement crackdown that required emergency legislation authorizing city sheriffs to padlock unlicensed retailers.

MRTA also did not anticipate the gray-market intersection with hemp-derived cannabinoids (Delta-8 THC, HHC, THCP, others) that have proliferated nationally since the 2018 Farm Bill. New York's response, primarily via OCM rulemaking in 2024–2025, has been to bring hemp-cannabinoid retail under the same regulatory framework as cannabis, with mixed compliance results.

What the next five years look like

The market is approaching steady state. The CAURD overhang has largely cleared. Licensed retail counts have grown into the high three digits statewide. Adult-use sales have moved from "marginal" to "meaningful" in OCM's revenue reporting. The unlicensed market has contracted (though not disappeared) under the 2024–2025 enforcement push.

The major outstanding questions for the next phase are:

• Whether OCM's slow licensing pace can be sustainable as larger national operators (Curaleaf, Trulieve, Green Thumb) consolidate market positions in faster-rollout states and pressure to allow multi-state-operator entry into New York grows.
• How the medical program's practitioner-discretion standard holds up against potential federal rescheduling, which may impose more specific certification requirements on the medical-cannabis category.
• Whether the social-equity-first licensing produces durable Black- and Latino-owned operator businesses over a 10-year time horizon, or whether the structural disadvantages (access to capital, real-estate costs, brand-marketing budgets) cause early licensees to be acquired or driven out.

For now, New York's MRTA stands as a deliberate experiment: a deliberately slow, deliberately equity-prioritizing rollout, with the costs and benefits of that choice both visible at the five-year mark.